About this trial
Dementia is associated with a variety of neurovascular and neurometabolic abnormalities. Traditional imaging techniques used to investigate such abnormalities, such as Positron Emission Tomography and functional Magnetic Resonance Imaging, are not always well tolerated, have expensive start up and running costs, and are limited with regards to the types of experiments that can be performed as they can be highly sensitive to movement, are noisy, and have physical restrictions.
Near-infrared spectroscopy (NIRS) is a non-invasive neuroimaging technique which uses light in the near-infrared spectrum to detect relative changes in concentration of oxygenated and deoxygenated haemoglobin, and the oxidation state of Cytochrome C Oxidase. As such, NIRS can provide measures of brain oxygenation and metabolism. NIRS is less sensitive to movement, is well tolerated and has few contraindications. It is thus a promising candidate for use in clinics or in peoples' homes for monitoring dementia.
In the present study, the investigators aim to use both dual-wavelength and broadband NIRS in a range of dementia subtypes, including Alzheimer's Disease and Dementia with Lewy Bodies, and severities, including Mild Cognitive Impairment, to identify how brain oxygenation and metabolism is altered in dementia and across various clinical subgroups. The investigators also aim to determine the relationship between brain oxygenation and metabolism in dementia, and use machine learning approaches to identify optical biomarkers for dementia.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Lewy Body Dementia
Alzheimer's Disease
Mild Cognitive Impairment (MCI-LB or MCI-AD) OR
Cognitively normal for their education and age, with a MMSE score above 26 AND
Disqualifiers
Severe dementia
Unable to participate
A MMSE score below 12
A condition which influences metabolism or haemodynamics
Trial population
The target study population is people with dementia. This includes those with Alzheimer's Disease, Dementia with Lewy Bodies, as well as those in the intermediate stages of the disease, such as Mild Cognitive Impairment. We will also recruit healthy controls.
Trial design
Case-control
Cross-sectional
Treatments tested in this trial
Near-infrared Spectroscopy scan
Other interventionNear-infrared spectroscopy is a non-invasive neuroimaging technique which uses light in the near-infrared spectrum to measure changes in brain oxygenation and metabolism.
Magnetic Resonance Imaging scan
Other interventionMagnetic Resonance Imaging is a non-invasive neuroimaging technique which provides detailed structural images of the brain.
Treatment groups
Trial outcomes
Primary outcomes
Brain oxygenation
As measured with dual-wavelength NIRS. We will measure task-related relative changes in concentration in oxygenated and deoxygenated haemoglobin (µmol).
Brain metabolism
As measured with broadband NIRS. We will measure task-related changes in oxidation state of Cytochrome C Oxidase(µmol).
Cognitive behavioural data
Behavioural scores collected through the cognitive testing performed during NIRS scans. These include scores of memory function and word retrieval, e.g., accuracy of words recalled, reaction times.
Secondary outcomes
ACE-R score
Cognitive exam, out of 100%.
Rey Auditory Verbal learning test
Accuracy.
Geriatric depression scale
Number identified out of 15.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
University of Cambridge
Lead sponsor
Cambridgeshire and Peterborough NHS Foundation Trust
Collaborator
The Gianna Angelopoulos Programme for Science, Technology and Innovation
Collaborator
The Newton Trust
Collaborator
Alzheimer's Research UK
Collaborator